Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
AssigneeNyxis NeuroTherapies, Inc.
InventorsJoseph R. Moskal, James F. Grutsch
Life of this patent
Estimating the term…
Abstract
The present invention relates to an assay for the detection of modified nucleoside levels in a patient. Detection of the modified nucleoside levels in a patient having a disease such as cancer allows for the progression of the disease to be followed and therapeutic regimens to be altered. Such an assay is particularly useful in following the response of cancer patients to chemotherapeutic treatment.
Claims40
A method for determining the effectiveness of a treatment regimen for cancer comprising determining the concentration of the modified nucleoside 7-methylinosine in a test sample of bodily fluid of a patient wherein a decreased amount of the modified nucleoside in the test sample relative to the amount of the modified nucleoside detected in a control sample of bodily fluid isolated from the patient prior to treatment indicates that the treatment regimen is effective.
A method for determining the effectiveness of a treatment regimen for brain cancer comprising determining the concentration of the modified nucleoside 1-methyladenosine in a test sample of bodily fluid of a patient wherein a decreased amount of the modified nucleoside in the test sample relative to the amount of the modified nucleoside detected in a control sample of bodily fluid isolated from the patient prior to treatment indicates that the treatment region is effective.
A method for determining the effectiveness of a treatment regimen for treating cancer comprising:
- a) adding to a test sample of bodily fluid of a patient to be treated a first antibody comprising a detectable label and having immunological reactivity to the modified nucleoside 7-methylinosine;
- b) contacting the test sample of step (a) with a solid surface to which a second antibody specific to the modified nucleoside is bound under conditions suitable to the formation of a complex of the modified nucleoside with the first antibody and the second antibody;
- c) detecting the first antibody of the complex;
- and
- d) comparing the amount of modified nucleoside in the test sample to the amount of the modified nucleoside in a control sample of bodily fluid isolated from the patient prior to treatment;
- wherein detection of a lower amount of modified nucleoside in the test sample as compared to the control sample indicates that the treatment regimen is effective.
A method for determining the effectiveness of a treatment regimen for treating brain cancer comprising:
- a) adding to a test sample of bodily fluid of a patient to be treated a first antibody comprising a detectable label and having immunological reactivity to 1-methyladenosine;
- b) contacting the test sample of step (a) with a solid surface to which a second antibody specific to a modified nucleoside is bound under conditions suitable to the formation of a complex of the modified nucleoside with the first antibody and the second antibody;
- and
- c) detecting the first antibody of the complex;
- and
- d) comparing the amount of modified nucleoside in the test sample to the amount of modified nucleoside in a control sample of bodily fluid isolated from the patient prior to treatment;
- wherein detection of a decreased amount of modified nucleoside in the test sample as compared to the control sample indicates that the treatment regimen is effective.
A method for diagnosing cancer comprising determining the concentration of the modified nucleoside 7-methylinosine in a test sample of bodily fluid of a patient suspected of having cancer wherein an increased level of modified nucleoside detected in the test sample relative to a control sample indicates the presence of cancer.
A method for diagnosing brain cancer comprising determining the amount of 1-methyladenosine in a test sample of bodily fluid of a patient suspected of having brain cancer wherein an increased amount of modified nucleoside in the test sample relative to a control sample indicates the presence of brain cancer.
A method for assisting in the diagnosis of cancer comprising:
- a) adding to a test sample of bodily fluid of a patient a first antibody comprising a detectable label and having immunological reactivity to 7-methylinosine;
- b) contacting the test sample of step (a) with a solid surface to which a second antibody specific to a modified nucleoside is bound under conditions suitable to the formation of a complex of said modified nucleoside with the first antibody and the second antibody;
- c) detecting the first antibody of the complex;
- and
- (d) comparing the amount of modified nucleoside detected in the test sample to a control sample;
- wherein detection of modified nucleoside in the test sample at an amount greater than that observed in the control sample indicates the presence of cancer.
A method for assisting in the diagnosis of brain cancer comprising:
- a) adding to a test sample of bodily fluid of a patient a first antibody comprising an detectable label having immunological reactivity to 1-methyladenosine;
- b) contacting the test sample of step (a) with a solid surface to which a second antibody specific to a modified nucleoside is bound under conditions suitable to the formation of a complex of said modified nucleoside with the first antibody and the second antibody;
- c) detecting the first antibody of the complex;
- and
- d) comparing the amount of modified nucleoside detected in the test sample to that of a control sample;
- wherein detection of modified nucleoside in the test sample at an amount greater than that observed in the control sample indicates the presence of cancer.
Dependencies are inferred from the claim text.